Blue Jet Healthcare Limited — Q2 FY26 earnings call

Call held 4 Nov 2025

Management summary

Blue Jet Healthcare reported a challenging Q2 FY26 with significant sequential revenue declines in both Contrast Media and PI-API segments, primarily attributed to increased transit times impacting revenue recognition and phasing of orders. Despite this, H1 FY26 performance showed robust YoY growth in revenue and EBITDA, driven by strong PI-API segment growth. The company is aggressively pursuing capacity expansion with major CAPEX plans for Mahad and Vizag, focusing on backward integration, new sweeteners, and peptide fragments, while maintaining strong margins and a debt-free balance sheet.

Highlights

  • Q2 FY26 Revenue from operations (excl. other income) was ₹165 crores, a decrease of 54% QoQ and 21% YoY.

  • H1 FY26 Revenue from operations was ₹518 crores, an increase of 40% YoY.

  • Q2 FY26 EBITDA stood at ₹60.1 crores with a 36% margin, up 14% YoY.

  • H1 FY26 EBITDA was ₹182 crores with a 35% margin, growing 41% YoY.

  • Q2 FY26 PAT was ₹43.2 crores (26% margin), while H1 FY26 PAT was ₹134.2 crores, representing 36% YoY growth.

  • Contrast Media Q2 revenue was ₹81 crores, down 17% QoQ, with only 55% of production recognized due to increased transit times.

  • Pharma Intermediates & API (PI-API) Q2 revenue was ₹42 crores, down 80% QoQ due to phasing, but H1 revenue grew 113% YoY to ₹255 crores.

  • The company remains debt-free with ₹341 crores in liquidity, supporting significant expansion plans including a ₹1,000 crore Phase-I CAPEX for a 103-acre Vizag site.

Key financials

2 periods

Q2

  • Revenue
    ₹165 Cr
    YoY -21% QoQ -54%
  • EBITDA
    ₹60.1 Cr
    YoY +14%
  • EBITDA Margin
    36%
    QoQ -1%
  • PAT
    ₹43.2 Cr
    QoQ +6%
  • PAT Margin
    26%
  • Gross Margin
    65%
  • Other Income
    ₹24 Cr

H1

  • Revenue
    ₹518 Cr
    YoY +40%
  • EBITDA
    ₹182 Cr
    YoY +41%
  • EBITDA Margin
    35%
    YoY +3%
  • PAT
    ₹134.2 Cr
    YoY +36%
  • Gross Margin
    54%

What they filed

Q1 FY27: revenue down 17.5%, net profit down 14.3% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue208 318 340 355 165 −21%192 −40%235 −31%293 −17%
EBITDA69 124 140 121 55 −20%47 −62%71 −49%98 −19%
Net profit58 99 110 91 52 −10%40 −60%64 −42%78 −14%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

SegmentRevenue (Q2)Revenue (H1)
Contrast Media₹81 Cr₹178 Cr
Pharma Intermediates and API (PI-API)₹42 Cr₹255 Cr
High-intensity Sweeteners——

Guidance & targets

Capacity

  • Mahad backward integration facility commissioning Capacity · H2 FY26 · High confidence on track
    In Mahad, our backward integration facility is on track for commissioning by H2 FY '26.

    — Mr. V. K. Singh, Chief Operating Officer

  • Vizag capacity addition Capacity · next 2-3 years · High confidence 1,000 KL
    In the next 2-3 years, we will maintain this growth momentum and will add another 1,000 KL capacity to keep in step with the aspiration, to keep in step with the medium-term goals and the requirements of our clients.

    — Mr. V. K. Singh, Chief Operating Officer

Capex

  • Mahad CAPEX Capex · ongoing · High confidence ₹300 crores

    Previously ₹250 crores → ₹300 crores

    We envisage that the earlier planned CAPEX of Rs. 250 crores that we had spoken to you about, this will increase to about Rs. 300 crores because of this automation.

    — Mr. V. K. Singh, Chief Operating Officer

  • R&D center Hyderabad CAPEX Capex · ongoing · High confidence ₹40 crores
    To respond to this surge in RFPs, a state-of-the-art R&D center is being planned at a cost of about Rs. 40 crores

    — Mr. V. K. Singh, Chief Operating Officer

  • Vizag Phase-I CAPEX Capex · by FY28 · High confidence ₹1,000 crores
    In Phase-I, at an approximate CAPEX of Rs. 1,000 crores, we are planning 4 blocks... We envisage that by FY '28, we will complete Phase-I.

    — Mr. V. K. Singh, Chief Operating Officer

Project Timeline

  • Vizag Phase-I completion Project Timeline · by FY28 · High confidence complete Phase-I
    We envisage that by FY '28, we will complete Phase-I.

    — Mr. V. K. Singh, Chief Operating Officer

  • Vizag groundbreaking Project Timeline · coming quarter · High confidence done
    the groundbreaking will be done in the coming quarter.

    — Mr. V. K. Singh, Chief Operating Officer

Profitability

  • EBITDA margin Profitability · full year · Medium confidence about 35%
    And for the full year, we should be maintaining the EBITDA of about 35% or so, right? That is what we have been doing? There is no change in that kind of? That should be the endeavor.

    — Mr. Shiven Arora, Managing Director

Product Commercialization

  • New iodinated intermediate Product Commercialization · Q4 FY26 · High confidence go commercial
    new iodinated intermediate is expected to go commercial in Q4 with encouraging outlook by the customer.

    — Mr. Shiven Arora, Managing Director

  • Onco and CNS candidates commercialization Product Commercialization · FY27 · Medium confidence commercialized
    I think we are looking at FY '27 for this.

    — Mr. V.K. Singh, Chief Operating Officer

Market Share

  • New Sweetener world market share Market Share · long-term vision · Medium confidence 10%
    Over here also, our endeavor would be to reach to that 10% in a long-term vision.

    — Mr. Shiven Arora, Managing Director

Market Opportunity

  • Onco and CNS candidates market size (individually) Market Opportunity · long-term · High confidence more than a billion dollars
    So, they are blockbusters, which means that they are all, the end formulation market is more than a billion dollars. Individually, for all three of them?

    — Mr. V.K. Singh, Chief Operating Officer

  • Bempedoic Acid patent protection Market Opportunity · till 2031 · High confidence till 2031
    It is patent protected till 2031.

    — Mr. V.K. Singh, Chief Operating Officer

Growth

  • Bempedoic Acid quarterly growth Growth · last quarter · High confidence 10%-15%
    even in the last quarter, the molecule grew between 10%-15% quarter-on-quarter.

    — Mr. V.K. Singh, Chief Operating Officer

Capacity Utilization

  • PI-API facility utilization rate Capacity Utilization · annualized basis · Medium confidence 60%-65%
    But on an annualized basis, like we said in the previous call, about 60%-65% capacity utilization. And we believe that we would stay in that range.

    — Mr. V. K. Singh, Chief Operating Officer

Risks & concerns

  • Increased transit times impacting revenue recognition

    medium

    Geopolitical reasons increased transit time for Contrast Media shipments to 60 days (from 35-40 days), leading to lower Q2 revenue recognition despite higher production.

    Management acknowledged

  • Quarterly revenue and gross margin volatility

    medium

    Customer off-take patterns and transit time issues cause non-uniform shipments across quarters, leading to variability in reported financials, especially in Contrast Media.

    Management acknowledged

  • Competition in Bempedoic Acid market

    low

    Analyst raised concern about competitors expanding capacity; management cited strong CDAs, solid track record with innovators, and long-term contracts as protection.

    Analyst downplayed

  • Cost-revenue mismatch from new capacities (Vizag)

    low

    Analyst questioned potential for higher costs before revenue from new Vizag capacities. Management stated most costs would be capitalized, and growth in 18-24 months should sustain margins despite R&D and senior management expansion.

    Analyst addressed

Areas of evasion (2)

  • profitability by segment
  • exact patient numbers for Bempedoic Acid

Q&A highlights

2 direct
Contrast Media Revenue Recognition and Gross Margin Volatility Partial
During this quarter, the goods in transit is higher, resulting in lower recognition of sales compared to the total production. Out of the total production this quarter, only 55% of the sale was recognized. The remaining are in transit will be recognized in the subsequent quarter. We will discuss the gross margin impact separately because of this transit related issues.

Highlights the impact of external factors (transit time) on reported quarterly financials and explains the significant gross margin fluctuation, suggesting H1 or annual numbers are more representative.

Asked by Sudarshan from ASK ND-PMS

Pharma Intermediate (Bempedoic Acid) Growth and Future Molecule Contributions Direct
I think the way the molecule is behaving and the way it has been able to capture newer markets. And most importantly, in such a molecule, we should see the prescription trends. So, they are also consistently increasing. Considering our position in this space, working closely with the innovator, we believe that we should be able to capture a significant part of this projected growth, at least for the full patient-protected cycle. ... FY '27 and beyond.

Provides insight into the growth trajectory of the key cardiovascular drug (Bempedoic Acid) and sets expectations for meaningful contributions from other pipeline molecules from FY27 onwards, addressing concerns about PI-API segment lumpiness.

Asked by Sudarshan from ASK ND-PMS

New High-Intensity Sweetener Opportunity and Vizag Plant Timeline Direct
So, it is a very established Sweetener. The overall market size is about a billion dollars. Today, we would be the only source manufacturing it out of India. What we have done in Saccharin, we want to replicate the same strategy. And what we had done in Saccharin, we were trying to capture 10% of the world market. Over here also, our endeavor would be to reach to that 10% in a long-term vision. ... Meaningful commercial volumes will come from Vizag. ... you will see capacities coming on stream in different phases, in FY '28, FY '29 and beyond.

Details a significant new product opportunity with a large market size and ambitious market share target, linking its commercialization to the large-scale Vizag CAPEX and providing a timeline for capacity ramp-up.

Asked by Sanjesh Jain from ICICI Securities

3 min read 6 chapters

Detailed narrative

Q2 FY26 Performance Overview and H1 Resilience

Blue Jet Healthcare reported Q2 FY26 revenue from operations of ₹165 crores, marking a significant 54% sequential decline and a 21% year-on-year decrease. This was primarily attributed to increased transit times affecting revenue recognition in the Contrast Media segment and phasing of orders in PI-API. Despite the Q2 dip, H1 FY26 revenue stood at a robust ₹518 crores, demonstrating a 40% year-on-year growth. EBITDA for Q2 was ₹60.1 crores with a 36% margin, up 14% YoY, while H1 EBITDA reached ₹182 crores (35% margin), growing 41% YoY, indicating sustained profitability despite revenue fluctuations.

Segmental Performance: Contrast Media and PI-API Dynamics

The Contrast Media segment recorded Q2 revenue of ₹81 crores, down 17% QoQ. Management clarified that only 55% of Q2 production was recognized as sales due to extended transit times (60 days vs. 35-40 days previously), with the remainder in transit for Q3 recognition. H1 Contrast Media revenue was ₹178 crores, consistent with the prior year. The Pharma Intermediates & API (PI-API) segment saw Q2 revenue of ₹42 crores, an 80% QoQ decline due to phasing, but H1 revenue surged 113% YoY to ₹255 crores, driven by cardiovascular drug intermediates. High-intensity Sweeteners grew 7% sequentially in Q2 and 3% YoY in H1.

Strategic Capacity Expansion and Backward Integration

The company is executing significant capacity expansion plans. The Mahad backward integration facility, a highly engineered plant for continuous flow synthesis of KSMs for Contrast Media, is on track for commissioning by H2 FY26. The CAPEX for this facility has been revised upwards to ₹300 crores (from ₹250 crores) due to automation, with ₹135 crores already incurred in H1. Additionally, a state-of-the-art R&D center is planned in Hyderabad with a CAPEX of ₹40 crores to support new chemistry platforms like peptides and biocatalysts.

Vizag Greenfield Project: A Long-Term Growth Driver

Blue Jet Healthcare has acquired a 103-acre land in Vizag for a globally competitive CDMO facility. Phase-I, with an approximate CAPEX of ₹1,000 crores, is planned to be completed by FY28. This phase will include four blocks: two for Contrast Media, one for a new high-intensity Sweetener, and a multipurpose block for new chemistries, including peptide fragments for GLPs. The groundbreaking is expected in the coming quarter, with capacities coming on stream in phases from FY28 onwards, aiming to add 1,000 KL capacity over the next 2-3 years.

New Product Opportunities and Market Outlook

Management highlighted promising new product developments. A new high-intensity Sweetener, with a global market size of approximately $1 billion, is being developed, with Blue Jet aiming for a 10% market share. This product will primarily be manufactured at the Vizag facility. The company is also tracking 20 RFPs, including 6 high-conviction Phase-III leads in the chronic space and an NCE for MRI, with commercialization for three late-stage Onco and CNS candidates expected by FY27, each representing a market opportunity of over $1 billion individually.

Financial Health and Margin Sustainability

Blue Jet Healthcare maintains a strong financial position, being debt-free with ₹341 crores in liquidity, primarily funding its expansion through internal accruals. Despite quarterly volatility, the company aims to maintain an EBITDA margin of around 35% for the full year. Gross margins for Q2 were 65% (vs. 48% in Q1), and H1 gross margins were 54%. Management emphasized that while quarterly variations are natural, the medium to long-term visibility remains strong, supported by order book momentum, customer lock-ins, and new validations.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls